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Sheep can be experimentally infected with bovine spongiform encephalopathy (BSE), and the ensuing
disease is similar to scrapie in terms of pathogenesis and clinical signs. BSE infection in sheep is an animal
and human health concern. In this study, the transmission in BoPrP-Tg110 mice of prions from BSE-infected
sheep was examined and compared to the transmission of original cattle BSE in cattle and sheep scrapie
prions. Our results indicate no transmission barrier for sheep BSE prions to infect BoPrP-Tg110 mice, but the
course of the disease is accelerated compared to the effects of the original BSE isolate. The shortened
incubation period of sheep BSE in the model was conserved in subsequent passage in BoPrP-Tg110 mice,
indicating that it is not related to infectious titer differences. Biochemical signature, lesion profile, and PrPSc
deposition pattern of both cattle and sheep BSE were similar. In contrast, all three sheep scrapie isolates tested
showed an evident transmission barrier and further adaptation in subsequent passage. Taken together, those
data indicate that BSE agent can be altered by crossing a species barrier, raising concerns about the virulence
of this new prion towards other species, including humans. The BoPrP-Tg110 mouse bioassay should be
considered as a valuable tool for discriminating scrapie and BSE in sheep.
Transmissible spongiform encephalopathies (TSEs) are neuro-
degenerative disorders occurring in sheep (scrapie), cattle (bovine
spongiform encephalopathy [BSE]), or humans (Creutzfeldt-
Jakob disease [CJD]). The infectious agents causing TSEs are
denoted prions (30). The only known constituent of prions is
PrPSc, an isoform of the cellular prion protein PrPC. The mech-
anism whereby PrPC is converted into PrPSc is poorly understood,
although the process is characterized by conformational changes
increasing the -sheet content: polymerization and insolubility of
the protein (23, 27, 31, 33, 35, 43). In most TSEs, PrPSc shows
partial resistance to degradation by proteinase K, yielding an
N-terminally truncated PrPres product (29).
BSE was recognized in the 1980s as a new prion disease (18).
In contrast, scrapie was identified over 200 years ago (25). BSE
has important implications for public health and has been
linked to the emergence of a new variant form of Creutzfeldt-
Jacob disease (vCJD) due to the consumption of BSE-contam-
inated beef products (4, 17, 39, 42). In general, prion trans-
mission in the same mammalian species is highly efficient and
cases show very similar incubation periods, whereas transmis-
sion between animals of different species is usually inefficient
(this restriction is termed the species barrier). Interspecies
transmission is accompanied by reduced infectivity and ex-
tended incubation periods and has the potential for new char-
acteristics to emerge (24, 26, 32). These putative characteristics
of prions after crossing the species barrier depend both on the
prion strain involved and the new host, rendering new prion
strains with features that differ from those of the original
strains. The species barrier could be modulated by the amino
acid sequence differences between the interacting PrP pro-
teins, a host factor and the prion strain being transmitted (8,
38), such that the transmission barrier for each prion strain is
specific for each donor-recipient species pair.
The possibility that BSE infection could occur in other species
such as sheep and goats has important implications for public
health. A goat with properties of BSE infection has been detected
in France and the United Kingdom (11, 20). BSE infection in
sheep has also been reported after experimental transmission
(14), as has natural BSE transmission between sheep (3). The
BSE susceptibility of sheep has extended to genotypes previously
classed as resistant to scrapie (19). Thus, BSE could be present in
sheep flocks showing similar signs to those observed in scrapie as
a recurrent infection, presumably at a low incidence (13). PrPres
from BSE-infected sheep shows certain differential biochemical
properties distinguishing it from PrPres obtained from scrapie-
infected sheep (40). However, the biological and molecular prop-
erties of the BSE strain after passage in sheep require careful
evaluation. Transgenic mice expressing the corresponding host
PrP protein and null for murine PrP are useful tools for analyzing
prion strain properties. The BoPrP-Tg110 transgenic mouse line
shows a high susceptibility to BSE prions and lacks an apparent
transmission barrier (6, 7), whereas a transmission barrier is evi-
dent when these transgenic mice are inoculated with sheep
scrapie prions (6, 7).
The present study was designed to compare the transmission
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of prions obtained from BSE-infected sheep, the original cattle
BSE prions, and sheep scrapie prions in the BoPrP-Tg110
mouse model. Our results show that prions from the BSE-
infected sheep isolate used are able to infect BoPrP-Tg110
mice without a transmission barrier and with enhanced viru-
lence compared to the original BSE isolate. In contrast, all
three sheep scrapie isolates tested were only transmitted to
BoPrP-Tg110 mice with an evident transmission barrier.
Pathological and biochemical features observed in the inocu-
lated BoPrP-Tg110 mice were also specific for the sheep BSE
isolate, revealing clear differences compared to the sheep
scrapie isolates.
MATERIALS AND METHODS
Mice model. The BoPrP-Tg110 mouse model was established as described
elsewhere (6). BoPrP-Tg110 transgenic mice express bovine PrP protein under
the murine PrP promoter in a murine PrP0/0 background. PrPC expression levels
in this mouse line are eightfold higher than the PrPC levels found in cow brain
homogenates.
TSE isolates. BSE5 was obtained from the brainstem of one cow naturally
infected with BSE (case 139) supplied by INRA (Nouzilly, France).
BSE/sheep inoculum. Seven ARQ/ARQ sheep were intracerebrally inoculated
with BSE5 in the framework of BSE in Sheep Project QLRT-2001-01309 (INRA-
Nouzilly, France). The BSE/sheep inoculum was obtained by pooling brainstems
from those seven sheep.
Sheep scrapie isolates. Three different sheep scrapie isolates were also used in
this study. (i) The SC-UCD-99 isolate was obtained from brain from an Irish
ARQ/ARQ sheep naturally infected with scrapie (provided by the Veterinary
Research Laboratory, Abbotstown, Ireland). (ii) The SC-Langlade isolate was
obtained from brain from a French ARQ/ARQ sheep naturally infected with
scrapie (provided by INRA, Toulouse, France). (iii) The SC-N662-97 isolate was
obtained from brain from a Spanish ARQ/ARQ sheep naturally infected with
scrapie. Brain homogenates from BoPrP-Tg110-inoculated and clinically affected
mice were collected and pooled for further passages.
Transmission studies. All inocula were prepared in sterile 5% glucose. To
minimize the risk of bacterial infection, all inocula were preheated for 10 min at
70°C before intracerebral inoculation in mice. The transmission experiment
design is illustrated in Fig. 1.
Groups of 10 to 12 mice (6 to 7 weeks old, weighing approximately 20 g) were
inoculated in the right parietal lobe using a disposable 25-gauge hypodermic
syringe. Twenty microliters of 10% brain homogenate containing similar
amounts of PrPres was delivered to each animal. To evaluate the clinical signs
appearing after inoculation, mice were observed daily and their neurological
status was assessed twice weekly. The presence of three signs of neurological
dysfunction (using 10 different diagnostic criteria) (36, 37) was necessary to score
a mouse positive for prion disease. When progression of the disease was evident,
the animals were killed for ethical reasons and their brains were harvested for
subsequent analysis. These specimens were used to evaluate the presence of
PrPres by Western blotting (WB) and enzyme-linked immunosorbent assay
(ELISA).
Western blotting. Frozen brain tissues from mice were homogenized in 5%
glucose in distilled water in grinding tubes (Bio-Rad) adjusted to 10% (wt/vol)
with TeSeE Precess 48 (Bio-Rad). Complete homogenization was finally ob-
tained by forcing the brain suspension through a 0.4-mm-diameter needle.
Briefly, 175  20 mg of each tissue was subjected to three 45-s cycles of homog-
enization (maximum speed in Ribolyser COGER) in 1.5 ml of a 5% glucose
solution. One hundred microliters of brain homogenate was precleared by cen-
trifugation at 2,000  g for 5 min in 5% sarcosyl. Samples were treated with 20
g/ml of proteinase K (Roche) at 37°C for 60 min, and insoluble fractions were
obtained by centrifugation at 25,000  g for 30 min. Sodium dodecyl sulfate
sample loading buffer was added to all samples, and each one was boiled for 10
min before loading onto an sodium dodecyl sulfate –12% polyacrylamide gel. For
the immunoblotting experiments, Sha31, 9A2, and 12B2 monoclonal antibodies
(MAbs) were used at 1 g/ml. Immunocomplexes were detected by horseradish-
peroxidase conjugated antimouse immunoglobulin G (IgG) (Amersham Phar-
macia Biotech). The immunoblots were developed under conditions of enhanced
chemiluminescence (Amersham Pharmacia Biotech). Fujifilm LAS-3000 was
used for image capture, and image analysis was performed using Image Gauge
4.0 software. SigmaPlot 2001 software was used for data analysis.
Epitope mapping antibodies. The mouse MAb Sha31 was used in purified
form, and 9A2 and 12B2 MAbs were used in the form of culture supernatants.
Sha31 was raised against proteinase K-treated and nondenatured scrapie-asso-
ciated fibrils of Syrian hamster infected brain (263K) and recognizes at least the
148YEDRYYRE155 epitope (numbered according to the sheep sequence) of the
PrP core (12). Mouse 9A2 and 12B2 MAbs were prepared at CIDC-Lelystad
from PrP-knockout mice (44) by immunizing them with a synthetic peptide
covering the domain corresponding to amino acids 97 to 115 of bovine PrP. The
9A2 epitope requires residues 102WNK104 and the 12B2 epitope requires resi-
dues 93WGQGG97 (numbered according to the sheep sequence in both cases).
All these sequences are conserved in sheep and bovine PrP protein.
FIG. 1. Overview of the inoculations conducted in BoPrP-Tg110 mice. Survival times (as days post inoculation)  standard error of the mean
and the percentage of animals scored PrPres positive are indicated.
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PrPSc proteinase K resistance ELISA. Two commercial test kits (TeSeE and
TeSeE sheep/goat by Bio-Rad) were used according to the manufacturer’s reco-
mmendations.
Each homogenate was incubated for 10 min at 37°C with 250 l of proteinase
K-buffer A solution. PrPSc was recovered as a pellet after addition of 250 l of
buffer B and centrifugation for 7 min at 20,000  g at 4°C. Supernatants were
discarded and pellets were dried. Finally, the pellet was solubilized in 25 l of
buffer C1 (5 min at 100°C) and diluted sixfold in R6 reagent. Aliquots of 100 l
were deposited and detected by the ELISA method. Denatured PrPSc is reacted
with capture antibody and tracer antibody successively (detection kit). The signal
linearity range for this ELISA was between 1.7 and 0.2 absorbance units. A
recombinant ovine PrPC specifically recognized by both in the immunometric
assay was used as internal standard to compare interassay results.
Each sample was diluted in negative 10% brain homogenate until a signal of
1.5 to 1.7 absorbance units was obtained. Equilibrated homogenates were ali-
quoted in a 12-microtube series (200 l per microtube) and subjected to pro-
teinase K digestion at concentrations ranging from 50 to 500 g/mg before PrPSc
precipitation. Finally the pellet was dissolved in 25 l of buffer C1 (5 min at
100°C) and diluted 12-fold in R6 reagent. Samples were deposited as triplicates
and detected using TeSeE or TeSeE sheep/goat (Bio-Rad).
Histopathology and immunohistochemistry. All procedures involving mice
brains and spleen were performed as previously described (1). Briefly, samples
were fixed in neutral-buffered 10% formalin (4% formaldehyde) before paraffin
embedding. After deparaffinization, 2-m-thick tissue sections were stained with
hematoxylin and eosin. Lesion profiles were established according to the stan-
dard method described by Fraser and Dickinson (15).
For PrPres immunohistochemistry, 3-m-thick sections were deparaffinized
before antigen retrieval. Briefly, sections were immersed in 98% formic acid for
7 min at room temperature and washed in running tap water before being
immersed in guanidine isothiocyanate for 1 h at 4°C. Guanidine isothiocyanate
treatment was followed by proteinase K digestion: TBS (50 mM Tris-HCl, 150
mM NaCl, pH 7.6) containing 20 g/ml of proteinase K for 15 min at 37°C.
Primary antibody incubation was conducted overnight at 4°C using the 2A11
MAb (2A11 MAb epitope, 171QVYYRPVDQ179 [amino acids of bovine PrP])
(5) diluted 1/400 in 10% normal goat serum. A secondary goat anti-mouse IgG
biotinylated antibody (DAKO) diluted 1/200 in 10% normal goat serum was
incubated for 30 min at room temperature, and an avidin-biotin-peroxidase
complex (Pierce) was applied using diaminobenzidine (DAB) as a substrate.
Finally, sections were counterstained with Mayer’s hematoxylin for 1 min, dehy-
FIG. 2. Histopathological alterations in BoPrP-Tg110 mice inoculated with BSE, BSE/sheep, or scrapie. (A) Vacuolation profiles in BSE-,
BSE/sheep-, and SC-UCD-99-inoculated animals. Lesion scoring is undertaken for seven areas of the brain (cerebral cortex, cerebellum, corpus
striatum, thalamus/hypothalamus, hippocampus, mesencephalon, and brainstem at the obex). Bars represent means  standard deviation.
(B) Images of vacuolation in the cerebellum and striatum of inoculated mice. The main differences are an increase in the number and size of
vacuoles in these areas of animals inoculated with scrapie compared to those in either the BSE- or BSE/sheep-inoculated animals.
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drated, and routinely mounted. Serial sections from positive controls and appro-
priate negative controls were included in each immunohistochemistry run.
RESULTS
Comparison of the biological properties of BSE, sheep BSE,
and scrapie in BoPrP-Tg110 mice. BoPrP-Tg110 mice were
inoculated with the BSE isolate BSE5 both before and after pas-
sage in ARQ/ARQ sheep (BSE/sheep inoculum) and compared
to three sheep scrapie isolates from different sources (see Fig. 1
for a scheme describing the inoculations). BoPrP-Tg110 mice
inoculated with BSE5 had a survival time of 303  10 days post-
inoculation (dpi). A similar survival time was observed in the
second passage (292 15 dpi). Those values were comparable to
those previously reported for another BSE isolate (BSE2; 308 
5 dpi) (6). All inoculated animals from both the first and second
passages were PrPres positive in the central nervous system. Taken
together, the 100% attack rate and the constant incubation period
observed in subpassage suggest an absence of transmission barrier
between cattle and BoPrP-Tg110 mice.
Inoculation of BoPrP-Tg110 mice with the three ARQ/ARQ
scrapie isolates (SC-UCD-99, SC-N662-97, and SC-Langlade)
indicated the existence of a clear transmission barrier in
BoPrP-Tg110 mice to the TSE agent isolated in sheep. Only
70% and 65% of the animals succumbed to, respectively, SC-
UCD-99 (survival time, 560  26 dpi) and SC-Langlade (sur-
vival time, 491  17 dpi.). None of the animals inoculated with
the SC-N662-97 isolate showed clinical signs, and when eutha-
nized (after 600 dpi), all them were PrPres positive. Second
passage of SC-UCD-99 resulted in a shortened survival period
(289  14 days).
Strikingly, survival time of BSE/sheep-inoculated mice (gener-
ated from the same original BSE5) was 234  5 dpi, which rep-
resented a 2-month reduction of the survival time when compared
with the BSE5 inoculation. Second passage of BSE/sheep resulted
in an equivalent survival time (234  3 dpi). All animals from
those two subpassages were PrPres positive in brain.
Lesion profile and PrPres distribution pattern in BoPrP-
Tg110 mice. Lesion distributions and PrPres deposit patterns
were similar in BoPrP-Tg110 mice inoculated with BSE5 and
BSE/sheep (Fig. 2 and 3). Those features were maintained
FIG. 3. Immunohistochemical detection of PrPres in BoPrP-Tg110 mice inoculated with BSE, BSE/sheep, and scrapie. (A) Deposition scores
for the different types of PrPres deposits (IN, intraneuronal; IG, intraglial; GA, glial associated deposits; NR, neuropil deposits; VS, vascular; EP,
ependimary deposits; Plaque-like, amyloid plaque-like deposits) in the brain of BoPrP-Tg110 mice inoculated with BSE/sheep, BSE, or SC-UCD-
99; second passages of brain material from these inoculated mice are shown in panel B. (C) Illustrations of the immunohistochemical detection
of PrPres in the brain stem and hippocampus of inoculated animals. Plaque-like deposits appear in the brain stem and hippocampus of BSE- and
BSE/sheep inoculated animals, but not in the hippocampus of the SC-UCD-99-inoculated animals. PrP deposition in the brain stem of SC-UCD-
99-inoculated animals is observed as intraneuron staining.
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after second passage of those isolates in BoPrP-Tg110 mice.
In scrapie-inoculated mice, both lesion profile and PrPres
deposition pattern in brain (Fig. 2 and 3) were similar for all
three scrapie isolates tested but differed from BSE. Those
features were also maintained after second passage of the
SC-UCD-99 isolate in terms of vacuolar change and PrPres
distribution (Fig. 2 and 3). Clear PrPres deposits were observed
in the spleen of BoPrP-Tg110 mice inoculated with BSE or
BSE/sheep (data not shown). Conversely, no PrPres accumula-
tion was detected in the spleen of scrapie-inoculated BoPrP-
Tg110 mice. Identical results were observed after a second
passage in BoPrP-Tg110 mice.
PrPres biochemical signature in inoculated BoPrP-Tg110
mice is strain dependent. In original BSE5, BSE/sheep, or
BoPrP-Tg110 mice inoculated with BSE5 or BSE/sheep, no
differences could be observed in terms of PrPres (i) electro-
phoresis mobility (Fig. 4A, lanes 1 to 6) (ii) glycoprofile (Fig. 5),
or (iii) proteinase K resistance (Fig. 6A and B). Mice inocu-
lated in second passage, using both sources of inoculum, re-
tained similar characteristics. Taken together, those data sug-
gest that, despite modifications of biological properties, BSE
biochemical signature is highly conserved after crossing the
sheep/bovine species barrier.
Using our biochemical test panel, all three original scrapie
isolates were clearly distinguishable from BSE or BSE/sheep.
Electrophoresis mobilities and glycoprofiles were comparable for
all three isolates but different from those of BSE (Fig. 4A, lanes
7, 10, and 11; and Fig. 5). Those features are consistent with
numerous reports concerning classical scrapie-BSE comparison
(40). Proteinase K resistance was clearly higher in scrapie isolates
than in BSE and BSE/sheep (higher proteinase K resistance) but
varied between all three scrapie isolates (Fig. 6A).
FIG. 4. Electrophoretic profiles and antibody labeling of PrPres detected with the Sha31 (A), 12B2 (B), and 9A2 (C) MAbs. Lanes show the
original BSE5 inoculum (lane 1), BSE5-infected BoPrP-Tg110 mice (lane 2), second-passage BSE5 in BoPrP-Tg110 mice (lane 3), BSE/sheep (lane
4), BSE/sheep in BoPrP-Tg110 mice (lane 5), second-passage BSE/sheep in BoPrP-Tg110 mice (lane 6), scrapie field isolate SC-UCD-99 (lane7),
SC-UCD-99 in BoPrP-Tg110 mice (lane 8), second-passage SC-UCD-99 in BoPrP-Tg110 mice (lane 9), scrapie field isolate SC-Langlade (lane 10),
and scrapie field isolate SC-N662-97 (lane 11). Panels A, B, and C were loaded with the same quantities of extracted PrPres from each sample. MW,
molecular mass given in kilodaltons. (D) PrPres fragment yields are represented according to MAb reactivity. Arrows indicate proteinase K cleavage
points, as predicted by the PeptideCuter program of the EXPASY server (http://us.expasy.org/). Numbers reflect sheep/cattle PrP sequence
positions. Continuous lines represent the main PrPres fragments, and broken lines represent PrPres fragments found in minor proportions.
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The scrapie isolates inoculated in BoPrP-Tg110 mice
showed different behavior in the PrPSc proteinase K resistance
ELISA (Fig. 6B). Furthermore, differences were observed in
the transmission of the scrapie isolates to BoPrP-Tg110 mice
(Fig. 1A). These differences suggest that while these scrapie
isolates share a similar classical PrPres pattern, an unrevealed
biodiversity could exist among scrapie isolates.
A faster mobility than in the original SC-UCD-99 isolate
(Fig. 4A, lanes 7 and 8) was observed in the BoPrP-Tg110. This
mobility change is also maintained after a second passage in
BoPrP-Tg110 mice (Fig. 4A, lane 9). The glycoprofile pattern
was modified in both first and second passages of scrapie in
BoPrP-Tg110 mice, with a decreased proportion of diglycosy-
lated band (Fig. 5). The proteinase K resistance assessed in our
ELISA was reduced in scrapie isolates (SC-UCD-99 and SC-
Langlade) passaged in BoPrP-Tg110 mice compared to that in
the original isolates (Fig. 6B). All of those features clearly
demonstrate that conversely to BSE or BSE/sheep prions,
scrapie biochemical signature was not preserved after passage
in BoPrP-Tg110 mice.
PrPres epitope mapping. The molecular characteristics of
PrPres from BoPrP-Tg110 mice inoculated with BSE, BSE/
sheep, and scrapie were determined using MAbs 12B2 and
9A2 and compared to the PrPres from the original inocula. The
ability of MAbs 12B2 (WGQGG epitope) and 9A2 (WNK
epitope) to recognize both sheep and bovine PrPc was first
confirmed using samples not treated with proteinase K (data
not shown).
The 9A2 MAb allowed us to detect all the tested samples
with a similar electrophoresis mobility pattern to that estab-
lished using Sha31 (which is directed against the core of the
protein). This indicates that the 9A2 MAb epitope is protected
from proteinase K cleavage irrespective of the PrPres analyzed
(Fig. 4C).
In (i) BSE, (ii) BSE/sheep, and (iii) BSE or BSE/sheep
passaged in BoPrP-Tg110 mice (Fig. 4B, lanes 1 to 6), no signal
or faint signal could be observed using 12B2. These results
indicate that in BSE-derived prions (showing negative or faint
staining for the 12B2 MAb), the 12B2 epitope is poorly pro-
tected from proteinase K digestion, while in scrapie prions, this
epitope seems to be fairly well protected (see Fig. 4D for
interpretation). Interestingly, after the scrapie adaptations in
the BoPrP-Tg110 mice, the 12B2 epitope is not detected (Fig.
4B, lanes 8 and 9) indicating a change in the biochemical
FIG. 5. Triangular plot of the glycosyl fractions of PrPres after pro-
teinase K digestion and Western blotting using the Sha31 antibody. The
data shown are the means of six or more measurements obtained from
density scans in two or more different Western blots. To interpret the plot,
read the values for the diglycosyl, monoglycosyl, and aglycosyl fractions
along the left, base, and right axes of the triangle, respectively. For each
point, the sum of the three values is 100. As an example, the values for the
individual points marked by arrows are 64, 24, and 12% for the diglycosyl,
monoglycosyl, and aglycosyl fractions, respectively.
FIG. 6. Differential proteinase K (PK) resistance ELISA for PrPSc from the inoculum (A) and from the BoPrP-Tg110-inoculated mice (B).
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properties of the newly formed PrPres that allows proteinase K
to eliminate the 12B2 epitope (see Fig. 4D for interpretation).
DISCUSSION
Species barrier/strain barrier. The species barrier concept
considers that differences in the PrP amino acid sequence
confer a limitation for prion infection to occur in a different
host species (32). In our study, when BoPrP-Tg110 mice were
inoculated with cattle BSE, the transmission rate and stability
of the incubation period between the first and second passages
were consistent with the expected lack of species barrier in
transmission. Meanwhile, the difficulties encountered for pri-
mary transmission of the three ARQ/ARQ sheep scrapie iso-
lates to BoPrP-Tg110 mice and the further reduction of incu-
bation period in second passage also sustain the species
barriers concept. However, according to the species barrier
hypothesis, similar difficulties should have been encountered
for primary transmission into BoPrP-Tg110 of ARQ/ARQ
sheep BSE versus ARQ/ARQ scrapie isolates. Conversely to
this expectation, the 100% transmission rate and the stable
incubation duration between the primary and secondary pas-
sages of the sheep BSE isolate into BoPrP-Tg110 are consis-
tent with a total lack of transmission barrier.
Those observations, but also other reports (16, 21, 38)
strongly support that the species barrier not only depends on
the PrP amino sequence of the host and/or donor but also, with
equal or greater importance, depends on the considered TSE
agent. In that context, the term “strain barrier” should be used.
Alteration of virulence of the BSE agent after its propaga-
tion in sheep. In our experiment, an obvious shorter survival
period was observed in BoPrP-Tg110 mice inoculated with
BSE/sheep than in those inoculated with cattle BSE. Because
this feature was maintained after second passage in the mice
model, it cannot be considered to be linked to a higher infec-
tious titer in the initial inoculum nor that heterologous inter-
action between PrPSc from the BSE/sheep inoculum and bo-
vine PrPC leads to more efficient conversion of PrPC than the
homologous interaction, but must be considered as a modifi-
cation of biological properties of the agent.
Host susceptibility to prion has been shown to be altered on
passage through an intermediate species. For instance, ham-
sters are resistant to chronic wasting disease (CWD) from
mule deer. However hamsters become highly susceptible to
CWD after its passage in ferrets, and the hamster-adapted
CWD is transmissible to hamsters with high efficiency (2). To
our knowledge, this is the first time that propagation properties
of a prion agent on its natural PrP host (harboring the PrP
sequence of the species where the prion is isolated in nature)
are shown to be altered by the passage in another species.
Moreover, this enhanced virulence of the BSE agent after its
passage into sheep showed by the isolate used raise some
concern about its potential higher danger for other species,
including humans. Human species have been considered resis-
tant to sheep scrapie but susceptible to cattle BSE. In this
sense, human susceptibility to the BSE agent after its passage
in sheep is unknown. The potential for BSE after passage in
sheep to “jump” more easily to humans than directly from
cattle is presently being addressed. For that, the infectivity of
sheep-passaged BSE in comparison to the original cattle BSE
is being determined in transgenic mice expressing human PrP.
TSE biochemical characteristics after transmission in
BoPrP-Tg110 mice. Biochemical analysis of the PrPres from
BSE and BSE/sheep and their passage in BoPrP-Tg110 mice
(Fig. 4 to 6) showed the preservation of their biochemical
characteristics: (i) similar apparent molecular masses, (ii) sim-
ilar proteinase K resistance in the ELISA, (iii) no significant
differences in glycoprofiles, and (iv) slight or null reactivity
with MAb 12B2. The WB results indicated that proteinase K
cleavage eliminates most of the 12B2 epitope in PrPres from all
of the BSE-derived prions (amino acids 93 to 97 for sheep PrP
and amino acids 101 to 105 for bovine PrP; see Fig. 4D). This
cleavage is indeed a biochemical signature of BSE in sheep.
Western blotting with the MAb 9A2 revealed that its corre-
sponding epitope was present in all of the analyzed PrPres,
suggesting that amino-terminal proteinase K cleavage occurs
between both epitopes (Fig. 4D). The faint signal found using
the 12B2 MAb in all of the BSE-derived PrPres may be due to
a minor subpopulation of PrPres molecules preserving the 12B2
epitope. A recent study has shown the coexistence of PrPres
bands of 19 and 21 kDa in sCJD brain samples, but these
appeared in different ratios depending on the CJD type in each
case (28). It is not known if in infected brains the different
prion types coexist in dynamic equilibrium, or if each prion
type may show different band ratios that change according to
the experimental conditions, such as pH, metal ions, or pro-
teinase K activity (22, 41, 45). Another possibility is that for
each PrPSc type, nearby cleavage sites are proteolyzed in an
exclusive “either/or” fashion, whereby after the primary site
attack, the second site is not cleaved by the enzyme, as has
been previously described for the limited proteolysis of avidin
with proteinase K (10). A main proteinase K cleavage point
would eliminate the 12B2 epitope, but if proteinase K previ-
ously attacks an adjacent unprotected site, this would create a
portion of PrPres harboring the 12B2 epitope (in a small per-
centage), explaining the faint signal that may be detected with
the 12B2 MAb.
BSE and BSE/sheep showed similar behavior in the PrPSc
proteinase K resistance ELISA, and this behavior was clearly
different from the higher proteinase K resistance shown by the
different scrapie isolates tested, allowing the discrimination
between BSE and scrapie in sheep. Interestingly, when BoPrP-
Tg110 mice were inoculated with scrapie, the PrPSc generated
was proteinase K sensitive and behaved similarly but not iden-
tically to the BSE strain (Fig. 6), indicating that scrapie is not
able to maintain its proteinase resistance when adapted to
bovine PrP, as was also found by WB with the 12B2 MAb.
Glycosyl fractions did not show remarkable changes in inocu-
lated BoPrP-Tg110 mice when compared to their correspond-
ing original inocula, except for scrapie, which showed a signif-
icant change in PrPres glycosyl fractions after passage in
BoPrP-Tg110 mice (Fig. 5), in line with its adaptation after
crossing the transmission barrier. Taken together, these results
suggest that the biochemical and biological properties of pri-
ons generated in BoPrP-Tg110 mice are influenced by the
inoculated prion strain. When the BSE prion strain (BSE or
BSE/sheep) is inoculated, no transmission barrier is observed
and all properties are conserved, irrespective of the inoculated
PrPres amino acid sequence (ovine or bovine). On the contrary,
VOL. 81, 2007 SHEEP BSE IN TRANSGENIC MICE 841
 at LAN
D
BO
UW
UNIVERSITEIT on Novem
ber 19, 2008 
jvi.asm.org
D
ow
nloaded from
 
when another strain such as sheep scrapie is used as the ino-
culum, the biochemical properties of the PrPres change dras-
tically from those shown in the original inoculum and are
different from the PrPres obtained when the BSE prion strain
(BSE or BSE/sheep) is inoculated (Fig. 5), indicating that the
scrapie strain adapts after crossing the transmission barrier.
Discrimination between scrapie and BSE in sheep using
BoPrP-Tg110 mice. Histological examination of inoculated
BoPrP-Tg110 mice revealed that BSE and sheep-passaged
BSE exhibit unique and similar lesion profiles and PrPres dis-
tribution patterns. Those typical features are preserved after a
second passage in BoPrP-Tg110 mice but differed from those
exhibited by scrapie in both first and second passages in
BoPrP-Tg110 mice.
The consistent transmission barrier we observed for scrapie
transmission contrasts with results reported by other authors in
a different mouse bovine PrP transgenic model (no evidence of
a transmission barrier) (39). These apparently contradictory
results may be due to differences in (i) the scrapie isolates used
(different agents or infectious titer) and (ii) the bovine-PrP
transgenic mouse lines. In parallel, inoculations of scrapie iso-
lates in cattle have been described showing transmission bar-
rier (34) or no transmission barrier (9) but with remarkable
differences in the experimental conditions used in each case.
To clarify this point, we requested the scrapie inocula used
in references 38 and 39. Unfortunately our request could not
be satisfied due to the limited quantity of material available.
Work in progress using other scrapie isolates with different
biochemical and genetic properties will improve our under-
standing of the behavior of scrapie prions in BoPrP-Tg110
mice and their putative potential as a tool for BSE strain
discrimination.
The shorter incubation period and lack of transmission bar-
rier observed with BSE agent compared to scrapie isolates,
combined with the lesional profile found in each case, suggest
that BoPrP-Tg110 mice could be a valuable and powerful tool
for the identification of the BSE agent. Experiments using a
large panel of natural TSE strains are ongoing in order to
validate the abilities of that mouse model to identify specifi-
cally the BSE agent putatively propagated in different species.
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